Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Basal insulin and cardiovascular and other outcomes in dysglycemia.

ORIGIN Trial Investigators., Gerstein HC, Bosch J, Dagenais GR, Díaz R, Jung H, Maggioni AP, Pogue J, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):319-28. doi: 10.1056/NEJMoa1203858. Epub 2012 Jun 11.

2.

n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.

ORIGIN Trial Investigators., Bosch J, Gerstein HC, Dagenais GR, Díaz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydén LE, Yusuf S.

N Engl J Med. 2012 Jul 26;367(4):309-18. doi: 10.1056/NEJMoa1203859. Epub 2012 Jun 11.

3.

Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, Celermajer D, Simes RJ, Rajamani K, Stanton K; FIELD Study Investigators..

Diabetes Care. 2012 Feb;35(2):218-25. doi: 10.2337/dc11-1109. Epub 2011 Dec 30.

4.

The metabolic syndrome predicts incident congestive heart failure: a 20-year follow-up study of elderly Finns.

Wang J, Sarnola K, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J.

Atherosclerosis. 2010 May;210(1):237-42. doi: 10.1016/j.atherosclerosis.2009.10.042. Epub 2009 Nov 10.

PMID:
19945701
5.

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial.

Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team..

Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6.

PMID:
19501900
6.

The metabolic syndrome predicts incident stroke: a 14-year follow-up study in elderly people in Finland.

Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J.

Stroke. 2008 Apr;39(4):1078-83. doi: 10.1161/STROKEAHA.107.499830. Epub 2008 Mar 6.

7.

Metabolic syndrome and incident end-stage peripheral vascular disease: a 14-year follow-up study in elderly Finns.

Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J.

Diabetes Care. 2007 Dec;30(12):3099-104. Epub 2007 Sep 11.

PMID:
17848614
8.

The metabolic syndrome predicts cardiovascular mortality: a 13-year follow-up study in elderly non-diabetic Finns.

Wang J, Ruotsalainen S, Moilanen L, Lepistö P, Laakso M, Kuusisto J.

Eur Heart J. 2007 Apr;28(7):857-64. Epub 2007 Feb 15.

PMID:
17303589
9.

Beneficial effect of prolyl oligopeptidase inhibition on spatial memory in young but not in old scopolamine-treated rats.

Jalkanen AJ, Puttonen KA, Venäläinen JI, Sinervä V, Mannila A, Ruotsalainen S, Jarho EM, Wallén EA, Männistö PT.

Basic Clin Pharmacol Toxicol. 2007 Feb;100(2):132-8.

10.
11.

The 5-HT(2) receptor activation enhances impulsive responding without increasing motor activity in rats.

Koskinen T, Ruotsalainen S, Sirviö J.

Pharmacol Biochem Behav. 2000 Aug;66(4):729-38.

PMID:
10973510
12.

Activation of 5-HT2A receptors impairs response control of rats in a five-choice serial reaction time task.

Koskinen T, Ruotsalainen S, Puumala T, Lappalainen R, Koivisto E, Männistö PT, Sirviö J.

Neuropharmacology. 2000 Jan 28;39(3):471-81.

PMID:
10698013
13.

Blockade of muscarinic, rather than nicotinic, receptors impairs attention, but does not interact with serotonin depletion.

Ruotsalainen S, Miettinen R, MacDonald E, Koivisto E, Sirviö J.

Psychopharmacology (Berl). 2000 Feb;148(2):111-23.

PMID:
10663425
14.
15.

Systemic administration of atipamezole, an alpha 2-antagonist, can reduce scopolamine-induced hyperactivity in rats.

Niittykoski M, Hakkarainen V, Puumala T, Lappalainen R, Ruotsalainen S, Haapalinna A, Sirviö J.

Behav Pharmacol. 1997 Oct;8(5):465-70.

PMID:
9832985
16.

5-HT1A receptor agonist (8-OH-DPAT) and 5-HT2 receptor agonist (DOI) disrupt the non-cognitive performance of rats in a working memory task.

Ruotsalainen S, MacDonald E, Koivisto E, Stefanski R, Haapalinna A, Riekkinen P Jr, Sirviö J.

J Psychopharmacol. 1998;12(2):177-85.

PMID:
9694031
17.

The role of the dorsal raphe-serotonergic system and cholinergic receptors in the modulation of working memory.

Ruotsalainen S, Miettinen R, MacDonald E, Riekkinen M, Sirviö J.

Neurosci Biobehav Rev. 1998;22(1):21-31.

PMID:
9491938
18.

Differential effects of three 5-HT receptor antagonists on the performance of rats in attentional and working memory tasks.

Ruotsalainen S, Sirviö J, Jäkälä P, Puumala T, MacDonald E, Riekkinen P Sr.

Eur Neuropsychopharmacol. 1997 May;7(2):99-108.

PMID:
9169297
19.

Additive deficits in the choice accuracy of rats in the delayed non-matching to position task after cholinolytics and serotonergic lesions are non-mnemonic in nature.

Ruotsalainen S, MacDonald E, Miettinen R, Puumala T, Riekkinen P Sr, Sirviö J.

Psychopharmacology (Berl). 1997 Apr;130(4):303-12.

PMID:
9160845
20.

Lack of relationship between thalamic oscillations and attention in rats: differential modulation by an alpha-2 antagonist.

Puumala T, Björklund M, Ruotsalainen S, Riekkinen M, Jäkälä P, Haapalinna A, Björk E, Riekkinen P Jr, Sirviö J.

Brain Res Bull. 1997;43(2):163-71.

PMID:
9222529

Supplemental Content

Loading ...
Support Center